促红细胞生成素糖基化分析方法的研究进展  

Progress in research on glycosylation analysis of erythropoietin

作　　者：李凤 段淑娥[1] 霍燕燕[1] LI Feng, DUAN Shu-e, HUO Yan-yan(Key Laboratory for Surface Engineering and Remanufacturing of Shanxi Province, School of Chemical Engineering, X i＇an University, X i＇an 710065, Shanxi Province, Chin)

机构地区：[1]西安文理学院化学工程学院陕西省表面工程与再制造重点实验室,陕西西安710065

出　　处：《中国生物制品学杂志》2018年第3期328-331,336,共5页Chinese Journal of Biologicals

摘　　要：重组人促红细胞生成素(recombinant human erythropoietin,r Hu EPO)是糖蛋白类药物,临床上主要用于治疗肾性贫血。糖基化是影响促红细胞生成素(erythropoietin,EPO)药物质量、安全性和活性的关键因素。近年来,EPO药物的原始专利即将过期,生物仿制药(biosimilar)进入一个高速发展期。因此,亟需发展可有效评价其糖基化修饰形态的方法。本文对EPO药物的发展、糖基化与活性的关系及糖基化分析方法的最新研究进展作一综述。Recombinant human erythropoietin（rHuEPO） is a highly glycosylated protein hormone which is mainly used for the treatment of anemia associated with chronic renal disease in clinic. Glycosylation is one of the most critical factors affecting the quality, safety and potency of erythropoietin. Due to patent expirations, we expect biosimilar erythropoietins to play an increasing role in healthcare in coming years. It is urgent for reliable analytical characterization of EPO glycosylation. This paper reviews the progress in research on the development of EPO drugs, relationship between glycosylation and activity and the method for glycosylation analysis.

关 键 词：促红细胞生成素 糖基化 

分 类 号：O656.35[理学—分析化学]